Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Previously, Dr. Boshoff oversaw clinical research and product development activities for Pfizer’s Oncology portfolio, including 24 approved innovative cancer medicines and biosimilars in more ...

Schmeltz has headed Pfizer's global oncology business for the last year. Pfizer The breast-cancer drug had its first major data presentation just three years before its US approval in 2015, Pfizer ...

Pfizer shifts oncology chief Schmeltz to new strategy role as rare disease head Varma fills in By Zoey Becker, Angus Liu Sep 2, 2022 11:18am Pfizer Andy Schmeltz rare diseases cancer drugs ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

This release contains forward-looking statements about Pfizer Oncology; our anticipated operating and financial performance, including financial guidance and projections; changes to Pfizer’s ...

Pfizer has a new strategy for fighting cancer that could generate $5 billion a year. We got a look inside. Drug giant Merck just bought a biotech for $773 million, and it reveals the company's ...

Pfizer is acquiring the cancer-focused biotech in a $43 billion deal, the company announced Monday. The pharma giant, which shot into prominence during the COVID-19 pandemic with its vaccines, is now ...

Oncology will be a big part of that effort — Pfizer executives told investors earlier this year that they expect to have eight blockbuster cancer drugs by 2030, up from five now.

Pfizer Inc. today announced changes to its executive leadership team to further advance its aspirations to discover and develop new medicines and vaccines, with an emphasis on oncology. Under his ...